α-Lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-γ to ameliorate experimental autoimmune encephalomyelitis in mice

Clinical Science

Volumn 125, Issue 7, 2013, Pages 329-340

  Wang, Kai Chen ^a,b,c,d   Tsai, Ching Piao ^b,d   Lee, Chao Lin ^c,d   Chen, Shao Yuan ^e   Lin, Gu Jiun ^a   Yen, Mao Hsiung ^a   Sytwu, Huey Kang ^a   Chen, Shyi Jou ^a,f  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

lipoic acid; Experimental autoimmune encephalomyelitis; Immunomodulation; Multipl sclerosis; Proliferator activated receptor ; Regulatory T cell

Indexed keywords

ALPHA THIOCTIC ACID; HEME OXYGENASE 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIOCTIC ACID; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; INFLAMMATORY CELL; LYMPHOCYTE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPINAL CORD; SPLEEN; TH1 CELL; TH17 CELL; UPREGULATION;

ANIMALS; ANTIOXIDANTS; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HEME OXYGENASE-1; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PPAR GAMMA; SPLEEN; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; THIOCTIC ACID; UP-REGULATION;

EID: 84880105696     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120560     Document Type: Article

References (51)

1. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B. and Hartung, H. P. (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2, 201-211
2. Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K. and Iwakura, Y. (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566-573
3. McFarland, H. F. and Martin, R. (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8, 913-919
4. Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y. H., Wang, Y., Hood, L., Zhu, Z., Tian, Q. and Dong, C. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141
5. Bo, L., Dawson, T. M., Wesselingh, S., Mork, S., Choi, S., Kong, P. A., Hanley, D. and Trapp, B. D. (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36, 778-786
6. van der Goes, A., Brouwer, J., Hoekstra, K., Roos, D., van den Berg, T. K. and Dijkstra, C. D. (1998) Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J. Neuroimmunol. 92, 67-75
7. Schreibelt, G., van Horssen, J., van Rossum, S., Dijkstra, C. D., Drukarch, B. and de Vries, H. E. (2007) Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res. Rev. 56, 322-330
8. Hisahara, S., Okano, H. and Miura, M. (2003) Caspasemediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination. Neurosci. Res. 46, 387-397
9. Mirshafiey, A. and Mohsenzadegan, M. (2009) Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol. 31, 13-29
10. Wollin, S. D. and Jones, P. J. (2003) a-Lipoic acid and cardiovascular disease. J. Nutr. 133, 3327-3330
11. Harrihar, P., Christopher, H., Jaya, R., Candy, L., Amar, C., Renu, D., Theodore, K., Jefferson, C., Mitchell, A. and Stephen, B. (2005) A-Lipoic acid is a weak dual PPARa/γ agonist: an ester derivative with increased PPARa/γ efficacy and antioxidant activity. J. Appl. Res. 555, 510-523
12. Klotz, L., Burgdorf, S., Dani, I., Saijo, K., Flossdorf, J, Hucke, S., Alferink, J., Nowak, N., Beyer, M., Mayer, G. et al. (2009) The nuclear receptor PPAR γ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 206, 2079-2089
13. Hontecillas, R. and Bassaganya-Riera, J. (2007) Peroxisomeproliferator- activated receptor γ is required for regulatory CD4+ T cell-mediated protection against colitis. J. Immunol. 178, 2940-2949
14. Chen, S. J., Wang, Y. L., Kao, J. H., Wu, S. F., Lo, W. T., Wu, C. C., Tao, P. L., Wang, C. C., Chang, D. M. and Sytwu, H. K. (2009) Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Mol. Immunol. 47, 567-574
15. Hsieh, S., Chen, N., Tarbell, K., Liao, N., Lai, Y., Lee, K., Wu, S., Sytwu, H., Han, S. and McDevitt, H. (2000) Transgenic mice expressing surface markers for IFN-γ and IL-4 producing cells. Mol. Immunol. 37, 281-293
16. Marracci, G. H., Jones, R. E., McKeon, G. P. and Bourdette, D. N. (2002) a-Lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol. 131, 104-114
17. Morini, M., Roccatagliata, L., Dell'Eva, R., Pedemonte, E., Furlan, R., Minghelli, S., Giunti, D., Pfeffer, U., Marchese, M., Noonan, D. et al. (2004) a-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148, 146-153
18. Paintlia, A. S., Paintlia, M. K., Singh, I. and Singh, A. K. (2006) IL-4-induced peroxisome-proliferator-activated receptor gamma activation inhibits NF-γB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNS-demyelinating diseases. J. Immunol. 176, 4385-4398
19. Niino, M., Iwabuchi, K., Kikuchi, S., Ato, M., Morohashi, T., Ogata, A., Tashiro, K. and Onoe, K. (2001) Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome-proliferator-activated receptor-γ . J. Neuroimmunol. 116, 40-48
20. Schreiner, B., Heppner, F. L. and Becher, B. (2009) Modeling multiple sclerosis in laboratory animals. Semin. Immunopathol. 31, 479-495
21. Cho, K. J., Moini, H., Shon, H. K., Chung, A. S. and Packer, L. (2003) a-Lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes. Biochem. Pharmacol. 66, 849-858
22. Packer, L., Kraemer, K. and Rimbach, G. (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17, 888-895
23. El Midaoui, A., Wu, L., Wang, R. and de Champlain, J. (2006) Modulation of cardiac and aortic peroxisome-proliferatoractivated receptor-γ expression by oxidative stress in chronically glucose-fed rats. Am. J. Hypertens. 19, 407-412
24. El Midaoui, A. and de Champlain, J. (2002) Prevention of hypertension, insulin resistance, and oxidative stress by a-lipoic acid. Hypertension 39, 303-307
25. Mitsui, Y., Schmelzer, J. D., Zollman, P. J., Mitsui, M., Tritschler, H. J. and Low, P. A. (1999) a-Lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve. J. Neurol. Sci. 163, 11-16
26. Ziegler, D., Hanefeld, M., Ruhnau, K. J., Hasche, H., Lobisch, M., Schutte, K., Kerum, G. and Malessa, R. (1999) Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22, 1296-1301
27. Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M. et al. (2006) Oral treatment with a-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29, 2365-2370
28. Ziegler, D., Nowak, H., Kempler, P., Vargha, P. and Low, P. A. (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis. Diabetic Med. 21, 114-121
29. Hager, K., Kenklies, M., McAfoose, J., Engel, J. and Munch, G. (2007) a-Lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J. Neural Transm. Suppl. 189-193
30. Namaka, M., Crook, A., Doupe, A., Kler, K., Vasconcelos, M., Klowak, M., Gong, Y., Wojewnik-Smith, A. and Melanson, M. (2008) Examining the evidence: complementary adjunctive therapies for multiple sclerosis. Neurol. Res. 30, 710-719
31. Yadav, V., Marracci, G., Lovera, J., Woodward, W., Bogardus, K., Marquardt, W., Shinto, L., Morris, C. and Bourdette, D. (2005) Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler. 11, 159-165
32. Chaudhary, P., Marracci, G. H. and Bourdette, D. N. (2006) Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 175, 87-96
33. Mestre, L., Docagne, F., Correa, F., Loria, F., Hernangomez, M., Borrell, J. and Guaza, C. (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci. 40, 258-266
34. Chou, T. C., Shih, C. Y. and Chen, Y. T. (2011) Inhibitory effect of a-lipoic acid on platelet aggregation is mediated by PPARs. J. Agric. Food Chem. 59, 3050-3059
35. Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett-Racke, A. E., Drew, P. D. and Racke, M. K. (2002) Peroxisome-proliferator-activated receptor-γ agonist 15-deoxy-(12,14)-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515
36. Polak, P. E., Kalinin, S., Dello Russo, C., Gavrilyuk, V., Sharp, A., Peters, J. M., Richardson, J., Willson, T. M., Weinberg, G. and Feinstein, D. L. (2005) Protective effects of a peroxisomeproliferator- activated receptor-ß/d agonist in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168, 65-75
37. Storer, P. D., Xu, J., Chavis, J. and Drew, P. D. (2005) Peroxisome-proliferator-activated receptor-γ agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161, 113-122
38. Jackson, S. M., Parhami, F., Xi, X. P., Berliner, J. A, Hsueh, W. A., Law, R. E. and Demer, L. L. (1999) Peroxisome-proliferatoractivated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094-2104
39. Klotz, L., Schmidt, S., Heun, R., Klockgether, T. and Kolsch, H. (2009) Association of the PPARγ gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci. Lett. 449, 81-83
40. Natarajan, C., Muthian, G., Barak, Y., Evans, R. M. and Bright, J. J. (2003) Peroxisome-proliferator-activated receptor-γ - deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171, 5743-5750
41. Ogborne, R. M., Rushworth, S. A. and O'Connell, M. A. (2005) a-lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 25, 2100-2105
42. Chen, S. J., Wang, Y. L., Lo, W. T., Wu, C. C., Hsieh, C. W., Huang, C. F., Lan, Y. H., Wang, C. C., Chang, D. M. and Sytwu, H. K. (2010) Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162, 210-223
43. Koppal, T., Petrova, T. V. and Van Eldik, L. J. (2000) Cyclopentenone prostaglandin 15-deoxy-(12,14)-prostaglandin J2 acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res. 867, 115-121
44. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. and Kuchroo, V. K. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238
45. O'Connor, R. A., Prendergast, C. T., Sabatos, C. A., Lau, C. W., Leech, M. D., Wraith, D. C. and Anderton, S. M. (2008) Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181, 3750-3754
46. Ponomarev, E. D., Maresz, K., Tan, Y. and Dittel, B. N. (2007) CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J. Neurosci. 27, 10714-10721
47. Falcone, M., Rajan, A. J., Bloom, B. R. and Brosnan, C. F. (1998) A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J. Immunol. 160, 4822-4830
48. Kohm, A. P., Carpentier, P. A., Anger, H. A. and Miller, S. D. (2002) Cutting edge: CD4+ CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169, 4712-4716
49. Stephens, L. A., Malpass, K. H. and Anderton, S. M. (2009) Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur. J. Immunol. 39, 1108-1117
50. Dunn, S. E., Bhat, R., Straus, D. S., Sobel, R. A., Axtell, R., Johnson, A., Nguyen, K., Mukundan, L., Moshkova, M., Dugas, J. C. et al. (2010) Peroxisome-proliferator-activated receptor d limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J. Exp. Med. 207, 1599-1608
51. Schillace, R. V., Pisenti, N., Pattamanuch, N., Galligan, S., Marracci, G. H., Bourdette, D. N. and Carr, D. W. (2007) Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochem. Biophys. Res. Commun. 354, 259-264